On June 20, 2024, Director Sagar Lonial executed a significant transaction by selling 25,933 shares of TG Therapeutics Inc (TGTX, Financial). The shares were sold at a price of $16.69 each, as detailed in the SEC Filing. Following this transaction, the insider now owns 105,195 shares of the company.
TG Therapeutics Inc is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company aims to improve the quality of life and overall treatment experience for patients in need.
Over the past year, the insider has sold a total of 65,787 shares and has not made any purchases. This recent sale is part of a broader trend within the company, where there have been 6 insider sells and only 1 insider buy over the same timeframe.
The stock of TG Therapeutics Inc was trading at $16.69 on the day of the sale, giving the company a market cap of approximately $2.621 billion. The price-earnings ratio stands at 77.18, which is above the industry median of 26.96.
According to the GF Value, the intrinsic value of TG Therapeutics Inc is estimated at $387.25 per share, suggesting that the stock might be a possible value trap at its current price, with a price-to-GF-Value ratio of 0.04.
This insider sale could be of interest to investors tracking insider behaviors and evaluating the stock's valuation metrics, such as the price-sales ratio, price-book ratio, and price-to-free cash flow, all of which are components of the GF Value calculation.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
